Potent inhibition of HIV type 1 infection of mononuclear phagocytes by synthetic peptide analogs of HIV type 1 protease substrates

AIDS Research and Human Retroviruses

Volumn 12, Issue 9, 1996, Pages 777-782

  Dukes, Carol S ^a,b   Matthews, Thomas J ^a   Lambert, Dennis M ^c,d   Dreyer, Geoffrey B ^c,e   Petteway, Stephen R ^a,c   Weinberg, J Brice ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Trimerus   (United States)

^e Arris Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; SB 108842; SB 108922; SB 109026; SB 205078; SB 205569; SB 205700; SB 206135; SB 206343; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ARTICLE; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLOTTING; MACROPHAGE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEINASE INHIBITION; VIRUS REPLICATION;

EID: 0029954763     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.777     Document Type: Article

References (41)

1. Wong-Staal F and Gallo RC: Human T-lymphotropic retroviruses. Nature (London) 1985;317:395-403.
2. Baboonian C, Dalgleish A, Bountiff L, Gross J, Oroszlan S, Rickett G, Smith-Burchness C, Troke P, and Merson J: HIV-1 proteinase is required for synthesis of pro-viral DNA. Biochem Biophys Res Commun 1991;179:17-24.
3. Le Grice SF, Mills J, and Mous J: Active site mutagenesis of the AIDS virus protease and its alleviation by trans complementation. EMBO J 1988;7:2547-2553.
4. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, and Sigal IS: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-4690.
5. Roberts NA, Martin JA, Kinchington D, Broadhurst AV, Craig JC, Duncan IB, Galpin SA, Handa BK, Kay J, Krohn A, Lambert RW, Merrett JH, Mills JS, Parkes KEB, Redshaw S, Ritchie AJ, Taylor DL, Thomas GJ, and Machin PJ: Rational design of peptide-based HIV proteinase inhibitors. Science 1990;248:358-361.
6. 2 symmetric inhibitors of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1991;35:2209-2214.
7. Bugelski PJ, Kaplan JM, Hart TK, Miller J, Laydon JT, Lee JC, Dreyer GB, and Kirsh R: Effect of a human immunodeficiency virus protease inhibitor on human monocyte function. AIDS Res Hum Retroviruses 1992;8:1951-1958.
8. Bugelski PJ, Kirsh R, and Hart TK: HIV protease inhibitors: Effects on viral maturation and physiologic function in macrophages. J Leukocyte Biol 1994;56:374-380.
9. Holladay MW, Salituro FG, and Rich DH: Synthetic and enzyme inhibition studies of pepstatin analogues containing hydroxyethylene and ketomethylene dipeptide isosteres. J Med Chem 1987;30:374-383.
10. Pearl LH and Taylor WR: A structural model for the retroviral proteases. Nature (London) 1987;329:351-354.
11. Sham HL, Bolis G, Stein HH, Fesik SW, Marcotte PA, Plattner JJ, Rempel CA, and Greer J: Renin inhibitors. Design and synthesis of a new class of conformationally restricted analogues of angiotensinogen. J Med Chem 1988;31:284-295.
12. Ratner L, Haseltine W, Patarca R, Livak KJ, Starcich B, Josephs SF, Doran ER, Rafalski JA, Whitehorn EA, Baumeister K, et al.: Complete nucleotide sequence of the AIDS virus, HTLV-III. Nature (London) 1985;313:277-284.
13. Debouck C, Gorniak JG, Strickler JE, Meek TD, Metcalf BW, and Rosenberg M: Human immunodeficiency virus protease expressed in Escherichia coli exhibits autoprocessing and specific maturation of the gag precursor. Proc Natl Acad Sci USA 1987;84:8903-8906.
14. Meek TD, Dayton BD, Metcalf BW, Dreyer GB, Strickler JE, Gorniak JG, Rosenberg M, Moore ML, Magaard VW, and Debouck C: Human immunodeficiency virus 1 protease expressed in Escherichia coli behaves as a dimeric aspartic protease. Proc Natl Acad Sci USA 1989;86:1841-1845.
15. Darke PL, Leu CT, Davis LJ, Heimbach JC, Diehl RE, Hill WS, Dixon RA, and Sigal IS: Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. J Biol Chem 1989;264:2307-2312.
16. Kramer RA, Schaber MD, Skalka AM, Ganguly K, Wong-Staal F, and Reddy EP: HTLV-III Gag protein is processed in yeast cells by the virus Pol-protease. Science 1986;231:1580-1584.
17. Dreyer GB, Metcalf BW, Tomaszek TA Jr, Carr TJ, Chandler AC III, Hyland L, Fakhoury SA, Magaard VW, Moore ML, Strickler JE, Debouck C, and Meek TD: Inhibition of human immunodeficiency virus 1 protease in vitro: Rational design of substrate analogue inhibitors. Proc Natl Acad Sci USA 1989;86:9752-9756.
18. Dreyer GB, Lambert DM, Meek TD, Carr TJ, Tomaszek TA Jr, Fernandez AV, Bartus H, Cacciavillani E, Hassell AM, Minnich M, Petteway SR Jr, and Metcalf BW: Hydroxyethylene isostere inhibitors of human immunodeficiency virus-1 protease: Structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry 1992;31:6646-6659.
19. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan ID, Bruckhardt J, Burger HU, Bragman K, Pinching AJ, and Weber JN: Safety and activity of saquinavir in HIV infection. Lancet 1995;345:952-955.
20. Kempf DJ, Marsh KC, and Denissen JF: ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995;92:2484-2488.
21. Bender BS, Davidson BL, Kline R, Brown C, and Quinn TC: Role of the mononuclear phagocyte system in the immunopathogenesis of human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Rev Infect Dis 1988;10:1142-1154.
22. Meltzer MS, Nakamura M, Hansen BD, Turpin JA, Kalter DC, and Gendelman HE: Macrophages as susceptible targets for HIV infection, persistent viral reservoirs in tissue, and key immunoregulatory cells that control levels of virus replication and extent of disease. AIDS Res Hum Retroviruses 1990;6:967-971.
23. Meek TD, Lambert DM, Dreyer GB, Carr TJ, Tomaszek TA Jr, Moore ML, Strickler JE, Debouck C, Hyland LJ, Matthews TJ, Metcalf BW, and Petteway SR: Inhibition of HIV-1 protease in infected T-lymphocytes by synthetic peptide analogues. Nature (London) 1990;343:90-92.
24. Richman DD, Kornbluth RS, and Carson DA. Failure of dideoxynucleosides to inhbiit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 1987;166:1144-1149.
25. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Gartner S, Popovic M, Hao Z, Gerrard TL, Wilson YA, Johns DG, and Broder S: Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2′,3′-dideoxynucleosides. J Exp Med 1988;168:1111-1125.
26. Weinberg JB, Hobbs MM, and Misukonis MA: Recombinant human gamma-interferon induces human monocyte polykaryon formation. Proc Natl Acad Sci USA 1984;81:4554-4557.
27. Weinberg JB and Haney AF: Tumor cell killing by human blood monocytes and peritoneal macrophages: Lack of alteration by endotoxin or quenchers of oxygen free radicals. J Natl Cancer Inst 1983;70:1005-1011.
28. Gartner S, Markovits P, Markovitz DM, Kaplan MH, Gallo RC, and Popovic M: The role of mononuclear phagocytes in HTLV-III/LAV infection. Science 1986;233:215-219.
29. Shadduck PP, Weinberg JB, Haney AF, Bartlett JA, Langlois AJ, Bolognesi DP, and Matthews TJ: Lack of enhancing effect of human anti-human immunodeficiency virus type 1 (HIV-1) antibody on HIV-1 infection of human blood monocytes and peritoneal macrophages. J Virol 1991;65:4309-4316.
30. Recker DP: A monocyte-derived factor interferes with detection of reverse transcriptase in HIV-1 infection. AIDS Res Hum Retroviruses 1991;7:73-81.
31. Abdel-Meguid SS, Metcalf BW, Carr TJ, Demarsh P, DesJarlais RL, Fisher S, Green DW, Ivanoff L, Lambert DM, and Murthy KH: An orally bioavailable HIV-1 protease inhibitor containing an imidazole-derived peptide bond replacement: Crystallographic and pharmacokinetic analysis. Biochemistry 1994;33:11671-11677.
32. Perno CF, Bergamini A, Pesce CD, Milanese G, Capozzi M, Aquaro S, Thaisrivongs S, Tarpley WG, Zon G, D'Agostini C, Rocchi G, Garaci E, and Calio R: Inhibition of the protease of human immunodeficiency virus blocks replication and infectivity of the virus in chronically infected macrophages. J Infect Dis 1993;168:1148-1156.
33. Perno CF, Aquaro S, Rosenwirth B, Balestra E, Peichl P, Billich A, Villani N, and Calio R: In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages. J Leukocyte Biol 1994;56:381-386.
34. D'Aquila RT, Johnson VA, Welles SL, Japour AJ, Kuritzkes DR, DeGruttola V, Reichelderfer PS, Coombs RW, Crumpacker CS, Kahn JO, Richman DD, and the AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group: Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Intern Med 1995;122:401-408.
35. Kozal MJ, Kroodsma K, Winters MA, Shafer RW, Efron B, Katzenstein DA, and Merigan TC: Didanosine resistance in HIV-infected patients switched from zidovudine to didanosine monotherapy. Ann Intern Med 1994;121:263-268.
36. St. Clair MH, Hartigan PM, Andrews JC, Vavro CL, Simberkoff MS, Hamilton JD, and the VA Cooperative Study Group: Zidovudine resistance, syncytium-inducing phenotype, and HIV disease progression in a case-control study. J Acquir Immune Defic Syndr 1993;6:891-897.
37. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
38. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
39. Wain-Hobson S: Virological mayhem. Nature (London) 1995; 373:102.
40. Vella S: Update on HIV protease inhibitors. AIDS Clin Care 1995;7:79-83.
41. Mascolini M: AIDS task force grapples with faster access to protease drugs. J Int Assoc Physicians AIDS Care 1995;1:6-11.